Home » Functional dyspepsia, a new drug to treat recurrent symptoms

Functional dyspepsia, a new drug to treat recurrent symptoms

by admin
Functional dyspepsia, a new drug to treat recurrent symptoms

Bayer Launches New Phytotherapeutic Drug in Italy to Treat Functional Dyspepsia

MILAN – Functional dyspepsia, a gastrointestinal disorder that affects 11% of Italians, primarily women, has serious consequences on the everyday life of patients. The symptoms of this pathology include stomach pain, burning in the upper part of the abdomen after meals, early satiety, nausea, loss of appetite, frequent belching, heartburn, and abdominal swelling.

To address this widespread issue, Bayer has introduced a new phytotherapeutic drug called IberogastAdvance to the Italian market. This drop formula is produced without a medical prescription and is based on extracts of medicinal plants such as bitter iberis, cumin, peppermint, chamomile, and lemon balm.

According to Professor Vincenzo Stanghellini from UniBo Internal Medicine, the symptoms of functional dyspepsia can be caused by factors such as excessive gastric acid secretion, motor activity dysfunction in the stomach, and nerve hypersensitivity. Microscopic inflammation of the gastric and duodenal mucosa may also play a role in these dysfunctions.

IberogastAdvance is designed to address multiple recurrent symptoms associated with functional dyspepsia by helping the stomach accommodate food, promoting stomach emptying, counteracting inflammation, stimulating the stomach wall’s protective mechanisms, reducing nerve activity that sends painful signals, and modulating the microbiota.

The effectiveness of IberogastAdvance has been proven in four clinical studies, with results showing that the product’s effects increase over time. To raise awareness of the product and the issue of functional dyspepsia among pharmacists, Bayer has utilized the Club Bayer platform, where pharmacists can learn interactively about IberogastAdvance and the condition it treats.

See also  The risk of heart attack would increase by 53% by taking these common drugs according to a new study

By launching this new product and educating healthcare professionals about functional dyspepsia, Bayer is taking a step towards fulfilling its corporate mission of “Health for all, Hunger for none.”

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy